Xeligekimab: First Approval

Area of Science:

• Immunology
• Dermatology
• Pharmacology

Background:

• Interleukin-17A (IL-17A) is a key cytokine implicated in the pathogenesis of inflammatory diseases like plaque psoriasis.
• Targeting IL-17A offers a promising therapeutic strategy for managing autoimmune and inflammatory conditions.

Purpose of the Study:

• To summarize the development milestones of xeligekimab, a novel IL-17A-neutralizing monoclonal antibody.
• To highlight the recent approval of xeligekimab for plaque psoriasis in China.

Main Methods:

• Xeligekimab is a recombinant human immunoglobulin (Ig)G4 monoclonal antibody designed to neutralize IL-17A.
• Mechanism of action involves blocking the IL-17A receptor interaction, inhibiting downstream inflammatory signaling.

Main Results:

• Xeligekimab received approval in China on August 27, 2024, for adult patients with moderate-to-severe plaque psoriasis.
• The drug is also under regulatory review for axial spondyloarthritis and in Phase II development for lupus nephritis.

Conclusions:

• The approval of xeligekimab represents a significant advancement in biologic therapies for plaque psoriasis.
• Xeligekimab's development trajectory indicates its potential as a therapeutic option for other IL-17A-mediated inflammatory diseases.